deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04109482

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

Sponsor: Mustang Bio

Conditions Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Interventions Cyclophosphamide Fludarabine MB-102
Updated 14 times since 2019 Last updated: Jul 19, 2024 Started: Feb 17, 2020 Primary completion: May 17, 2023 Completion: May 17, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business reasons.

Other terminated trials from Mustang Bio

More terminations from Mustang Bio

Other Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) trials with similar outcome

Browse all Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) trials

A PHASE1/PHASE2 clinical study on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), this trial is terminated or withdrawn. The trial is conducted by Mustang Bio and has accumulated 14 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~May 2022 · 14 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Jul 2023 · 3 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Aug 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

  3. Jul 2024 — Aug 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jul 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: Recruiting → Terminated

  5. Apr 2023 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 9 earlier versions

  1. Sep 2022 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

  2. May 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  3. Mar 2021 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Mar 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Nov 2019 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    Status: Recruiting → Not Yet Recruiting

  9. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mustang Bio
Data source: Mustang Bio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations